汉森制药(002412) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 235,387,600.31, representing a 35.01% increase compared to CNY 174,351,660.96 in the same period last year[7]. - Net profit attributable to shareholders was CNY 45,731,537.24, up 23.79% from CNY 36,943,574.88 year-on-year[7]. - Basic earnings per share were CNY 0.0909, reflecting a 23.84% increase from CNY 0.0734 in the same quarter last year[7]. - The company's operating profit for Q1 2021 was CNY 51.78 million, an increase of 20.3% from CNY 43.02 million in the same period last year[44]. - The total profit for Q1 2021 was CNY 51.79 million, an increase of 21.6% from CNY 42.54 million in Q1 2020[44]. - The total comprehensive income for Q1 2021 was CNY 41.99 million, a decrease of 15.5% from CNY 49.69 million in Q1 2020[42]. Cash Flow - The net cash flow from operating activities reached CNY 70,886,845.47, a significant increase of 1,325.96% compared to a negative cash flow of CNY 5,782,168.59 in the previous year[7]. - The cash flow from operating activities for Q1 2021 was CNY 70.89 million, a significant improvement compared to a negative cash flow of CNY 5.78 million in the same period last year[49]. - The net increase in cash and cash equivalents was CNY 13,213,916.83, a growth of 76.77%, attributed to the increase in net cash flow from operating activities[17]. - The total cash inflow from operating activities was CNY 191,560,827.13, compared to CNY 155,880,859.60 in the previous year, marking an increase of approximately 22.9%[51]. - The net cash flow from investing activities was -CNY 14,063,709.06, compared to -CNY 405,308.11 in the previous year, showing increased investment outflows[53]. - The net cash flow from financing activities was -CNY 31,612,220.24, contrasting with a positive net cash flow of CNY 28,495,809.77 in the same period last year[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,921,371,947.38, a 1.73% increase from CNY 1,888,641,664.49 at the end of the previous year[7]. - The company's total liabilities decreased to CNY 304,748,285.27 from CNY 310,340,450.87, a reduction of approximately 1.9%[37]. - The equity attributable to shareholders increased to CNY 1,668,458,110.60 from CNY 1,629,570,165.96, indicating a growth of about 2.4%[37]. - Cash and cash equivalents increased to CNY 89,794,057.91 from CNY 71,947,021.43, marking a rise of approximately 24.9%[34]. - Accounts receivable rose to CNY 204,273,523.74 from CNY 166,163,659.43, reflecting an increase of about 22.9%[34]. - The ending balance of other current assets decreased by CNY 22,307,819.74, a decline of 91.85%, primarily due to the offset of prepaid VAT by the parent company during the reporting period[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,411[11]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, amounting to 212,006,189 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Expenses and Costs - Operating costs rose by CNY 16,819,782.53, a growth of 36.90%, corresponding to the increase in sales revenue[15]. - Sales expenses increased by CNY 31,580,411.32, a growth of 40.96%, mainly due to increased sales activities during the reporting period[16]. - Research and development expenses for Q1 2021 amounted to CNY 5.22 million, up from CNY 4.37 million in Q1 2020, indicating a focus on innovation[44]. - The company reported a research and development expense of CNY 6,396,211.92, compared to CNY 5,184,895.94 in the previous year, reflecting an increase of approximately 23.3%[40]. Other Income and Gains - The company reported non-recurring gains and losses totaling CNY 788,560.30 for the reporting period[8]. - Other income increased by CNY 263,173.12, a growth of 41.37%, primarily due to a government subsidy received for the smart manufacturing system[16]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[44].